Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
